JPH10511682A - ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせ - Google Patents
ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせInfo
- Publication number
- JPH10511682A JPH10511682A JP8528931A JP52893196A JPH10511682A JP H10511682 A JPH10511682 A JP H10511682A JP 8528931 A JP8528931 A JP 8528931A JP 52893196 A JP52893196 A JP 52893196A JP H10511682 A JPH10511682 A JP H10511682A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- cis
- zidovudine
- oxathiolan
- cyclopentene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ジドブジン、(1S,4R)−シス−4−[2−アミノ−6−(シクロ プロピルアミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタ ノールおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1, 3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンから選択さ れる2つの化合物を含む組み合わせであって、但し、2つの化合物はジドブジン および(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1,3−オ キサチオラン−5−イル)−(1H)−ピリミジン−2−オンではない組み合わ せ。 2. ジドブジン、(1S,4R)−シス−4−[2−アミノ−6−(シクロ プロピルアミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタ ノールおよび(2R,シス)−4−アミノ−5−フルオロ−1−(2−ヒドロキ シメチル−1,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2− オンから選択される2つの化合物を含む組み合わせ。 3. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルアミ ノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノールまたは その生理学的機能性誘導体、ジドブジンまたはその生理学的機能性誘導体、およ び(2R,シス)−4−アミノ−(2−ヒドロキシメチル−1,3−オキサチオ ラン−5−イル)−(1H)−ピリミジン−2−オンまたはその生理学的機能性 誘導体を含む、請求項1に記載の組み合わせ。 4. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルアミ ノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノールまたは その生理学的機能性誘導体、ジドブジンまたはその生理学的機能性誘導体、およ び(2R,シス)−4−アミノ−5−フルオロ−1−(2−ヒドロキシメチル− 1,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンまたは その生理学的機能性誘導体を含む、請求項2に記載の組み合わせ。 5. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルアミ ノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノール:ジド ブジン:(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1,3− オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンの重量比が1〜 20:1〜20:1〜10である、請求項3に記載の組み合わせ。 6. 医学的治療に用いるための請求項1〜5のいずれか一項に記載の組み合 わせ。 7. 請求項1または5に記載の組み合わせとそのための1種以上の薬学的に 許容される担体とを含む医薬配合物。 8. 単位投薬の形の請求項7に記載の配合物。 9. HIV感染動物のHIV感染の症状または作用の治療または予防方法で あって、上記動物を、治療に有効な量の請求項1〜4のいずれか一項で定義した 通りの組み合わせで治療することを含む方法。 10. 組み合わせを同時に投与する、請求項9に記載の方法。 11. 組み合わせを順次投与する、請求項9に記載の方法。 12. 組み合わせを単一の組み合わせ配合物として投与する、請求項9に記 載の方法。 13. 上記動物が人間である、請求項9〜12のいずれか一項に記載の方法 。 14. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルア ミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノールの、 ジドブジンおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル− 1,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンと共に 同時または順次投与するためのHIV感染症の治療および/または予防用薬剤の 製造における使用。 15. ジドブジンの、(1S,4R)−シス−4−[2−アミノ−6−(シ クロプロピルアミノ)−9H−プリン−9−イル]−2−シクロペンテン−1− メタノールまたは(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル− 1,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンと共に 同時または順次投与するためのHIV感染症の治療用薬剤の製造における使用。 16. (2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1,3 −オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンの、(1S, 4R)−シス−4−[2−アミノ−6−(シクロプロピルアミノ)−9H−プリ ン−9−イル]−2−シクロペンテン−1−メタノールまたはジドブジンと共に 同時または順次投与するためのHIV感染症の治療用薬剤の製造における使用。 17. (2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1,3 −オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンの、(1S, 4R)−シス−4−[2−アミノ−6−(シクロプロピルアミノ)−9H−プリ ン−9−イル]−2−シクロペンテン−1−メタノールまたはジドブジンと共に 同時または順次投与するためのHIV感染症の治療用薬剤の製造における使用。 18. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルア ミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノール、ジ ドブジンおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1 ,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンの、HI V感染症の治療および/または予防用薬剤の製造における使用。 19. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルア ミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノール、ジ ドブジンおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1 ,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンの、HI V 感染症の治療および/または予防用薬剤の製造における使用。 20. ヌクレオシドまたは非ヌクレオシド抑制剤に対して耐性のHIV感染 症を治療および予防するための請求項14〜19のいずれか一項に記載の使用。 21. エイズの治療における請求項14〜19のいずれか一項に記載の使用 。 22. エイズ関連症状またはエイズ痴呆合併症の治療における請求項14〜 19のいずれか一項に記載の使用方法。 23. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルア ミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノール、ジ ドブジンおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1 ,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンから選択 される少なくとも1つの活性成分、並びに3つの活性成分全てを一緒に組み合わ せて用いる際の指導を含めた情報説明書を含む、患者パック。 24. (1S,4R)−シス−4−[2−アミノ−6−(シクロプロピルア ミノ)−9H−プリン−9−イル]−2−シクロペンテン−1−メタノール、ジ ドブジンおよび(2R,シス)−4−アミノ−1−(2−ヒドロキシメチル−1 ,3−オキサチオラン−5−イル)−(1H)−ピリミジン−2−オンから選択 される少なくとも1つの活性成分、並びに3つの活性成分全てを一緒に組み合わ せて用いる際の指導を含めた情報説明書を含む、患者パック。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9506490.3 | 1995-03-30 | ||
GBGB9506489.5A GB9506489D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
GBGB9506490.3A GB9506490D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
PCT/EP1996/001352 WO1996030025A1 (en) | 1995-03-30 | 1996-03-28 | Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10511682A true JPH10511682A (ja) | 1998-11-10 |
JP2954357B2 JP2954357B2 (ja) | 1999-09-27 |
Family
ID=26306774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8528931A Expired - Lifetime JP2954357B2 (ja) | 1995-03-30 | 1996-03-28 | ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせ |
Country Status (36)
Country | Link |
---|---|
US (1) | US6417191B1 (ja) |
EP (1) | EP0817637B1 (ja) |
JP (1) | JP2954357B2 (ja) |
KR (1) | KR100542536B1 (ja) |
CN (1) | CN1103593C (ja) |
AP (1) | AP652A (ja) |
AT (1) | ATE220551T1 (ja) |
AU (1) | AU715213B2 (ja) |
BR (3) | BR9607851B1 (ja) |
CA (1) | CA2216634C (ja) |
CZ (1) | CZ295940B6 (ja) |
DE (3) | DE122005000029I1 (ja) |
DK (1) | DK0817637T3 (ja) |
EA (1) | EA000626B3 (ja) |
EE (1) | EE04047B1 (ja) |
ES (1) | ES2179193T3 (ja) |
FR (1) | FR05C0022I2 (ja) |
GE (1) | GEP20022647B (ja) |
HK (1) | HK1009401A1 (ja) |
HU (1) | HU224010B1 (ja) |
IL (1) | IL117727A (ja) |
LU (1) | LU91171I2 (ja) |
MX (1) | MX9707316A (ja) |
MY (1) | MY115461A (ja) |
NL (1) | NL300195I2 (ja) |
NO (2) | NO313787B1 (ja) |
NZ (1) | NZ306419A (ja) |
OA (1) | OA10616A (ja) |
PL (1) | PL187085B1 (ja) |
PT (1) | PT817637E (ja) |
RO (1) | RO117995B1 (ja) |
SI (1) | SI0817637T1 (ja) |
SK (1) | SK283825B6 (ja) |
TR (1) | TR199701074T1 (ja) |
UA (1) | UA60293C2 (ja) |
WO (1) | WO1996030025A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9744181B2 (en) | 2003-01-14 | 2017-08-29 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ429498A3 (cs) * | 1996-06-25 | 1999-06-16 | Glaxo Group Limited | Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV |
US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
GB9709945D0 (en) * | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
WO1998052570A1 (en) * | 1997-05-17 | 1998-11-26 | Glaxo Group Limited | Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
AU769660B2 (en) * | 1997-05-17 | 2004-01-29 | Glaxo Group Limited | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
CA2374198A1 (en) * | 1998-05-29 | 1999-12-02 | Maki Arai | Combination therapy for treatment of fiv infection |
GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
AP2220A (en) * | 2001-05-11 | 2011-03-24 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
TW200403061A (en) * | 2002-06-04 | 2004-03-01 | Glaxo Group Ltd | Pharmaceutical compositions |
AU2004224191A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
DE602004030369D1 (de) | 2003-10-24 | 2011-01-13 | Immunaid Pty Ltd | Therapieverfahren |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 nnrt 저해제 |
JP5415957B2 (ja) | 2006-12-13 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての2−(ピペリジン−4−イル)−4−フェノキシ−又はフェニルアミノ−ピリミジン誘導体 |
WO2008095263A1 (en) * | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
EP2982978A1 (en) | 2009-05-27 | 2016-02-10 | Immunaid Pty Ltd | Methods of treating diseases |
EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
MX2016002560A (es) | 2013-08-29 | 2016-10-26 | Teva Pharma | Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir. |
AU2015245217A1 (en) | 2014-04-08 | 2016-10-13 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir |
CN117164657A (zh) | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
US11738087B2 (en) | 2015-09-08 | 2023-08-29 | Monash University | Lymph directing prodrugs |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
EP4306524A2 (en) * | 2017-08-29 | 2024-01-17 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0245486A (ja) * | 1988-06-27 | 1990-02-15 | Wellcome Found Ltd:The | 治療用ヌクレオシド類 |
WO1992015309A1 (en) * | 1991-03-06 | 1992-09-17 | The Wellcome Foundation Limited | Antiviral nucleoside combination |
WO1993023021A2 (en) * | 1992-05-13 | 1993-11-25 | The Wellcome Foundation Limited | Therapeutic combinations |
JPH06234641A (ja) * | 1991-05-16 | 1994-08-23 | Glaxo Group Ltd | 抗ウイルス組合せ |
EP1513917A1 (en) * | 2002-06-14 | 2005-03-16 | Degussa AG | Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
GB9417249D0 (en) | 1994-08-26 | 1994-10-19 | Wellcome Found | A novel salt |
US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
ATE230267T1 (de) | 1996-06-25 | 2003-01-15 | Glaxo Group Ltd | Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv |
CZ429498A3 (cs) | 1996-06-25 | 1999-06-16 | Glaxo Group Limited | Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV |
-
1996
- 1996-03-27 MY MYPI96001152A patent/MY115461A/en unknown
- 1996-03-28 KR KR1019970706824A patent/KR100542536B1/ko not_active IP Right Cessation
- 1996-03-28 CA CA002216634A patent/CA2216634C/en not_active Expired - Lifetime
- 1996-03-28 BR BRPI9607851-0A patent/BR9607851B1/pt active IP Right Grant
- 1996-03-28 TR TR97/01074T patent/TR199701074T1/xx unknown
- 1996-03-28 DE DE200512000029 patent/DE122005000029I1/de active Pending
- 1996-03-28 SK SK1295-97A patent/SK283825B6/sk not_active IP Right Cessation
- 1996-03-28 MX MX9707316A patent/MX9707316A/es active IP Right Grant
- 1996-03-28 EP EP96911953A patent/EP0817637B1/en not_active Expired - Lifetime
- 1996-03-28 GE GEAP19963898A patent/GEP20022647B/en unknown
- 1996-03-28 CZ CZ19973090A patent/CZ295940B6/cs not_active IP Right Cessation
- 1996-03-28 HU HU9801571A patent/HU224010B1/hu active Protection Beyond IP Right Term
- 1996-03-28 DE DE1996622386 patent/DE122005000029I2/de active Active
- 1996-03-28 BR BRPI9607851A patent/BRPI9607851B8/pt unknown
- 1996-03-28 BR BRPI9612992-1A patent/BRPI9612992B1/pt not_active IP Right Cessation
- 1996-03-28 ES ES96911953T patent/ES2179193T3/es not_active Expired - Lifetime
- 1996-03-28 JP JP8528931A patent/JP2954357B2/ja not_active Expired - Lifetime
- 1996-03-28 AP APAP/P/1997/001089A patent/AP652A/en active
- 1996-03-28 EE EE9700240A patent/EE04047B1/xx not_active IP Right Cessation
- 1996-03-28 SI SI9630494T patent/SI0817637T1/xx unknown
- 1996-03-28 AT AT96911953T patent/ATE220551T1/de active
- 1996-03-28 WO PCT/EP1996/001352 patent/WO1996030025A1/en active IP Right Grant
- 1996-03-28 PT PT96911953T patent/PT817637E/pt unknown
- 1996-03-28 AU AU54972/96A patent/AU715213B2/en not_active Expired
- 1996-03-28 EA EA199700203A patent/EA000626B3/ru not_active IP Right Cessation
- 1996-03-28 DE DE69622386T patent/DE69622386T2/de not_active Expired - Lifetime
- 1996-03-28 CN CN96194050A patent/CN1103593C/zh not_active Expired - Lifetime
- 1996-03-28 NZ NZ306419A patent/NZ306419A/xx not_active IP Right Cessation
- 1996-03-28 DK DK96911953T patent/DK0817637T3/da active
- 1996-03-28 US US08/930,225 patent/US6417191B1/en not_active Expired - Lifetime
- 1996-03-28 PL PL96322532A patent/PL187085B1/pl unknown
- 1996-03-28 RO RO97-01795A patent/RO117995B1/ro unknown
- 1996-03-28 UA UA97094740A patent/UA60293C2/uk unknown
- 1996-03-29 IL IL11772796A patent/IL117727A/xx not_active IP Right Cessation
-
1997
- 1997-09-17 OA OA70075A patent/OA10616A/en unknown
- 1997-09-29 NO NO19974510A patent/NO313787B1/no not_active IP Right Cessation
-
1998
- 1998-09-04 HK HK98110458A patent/HK1009401A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 LU LU91171C patent/LU91171I2/fr unknown
- 2005-05-09 FR FR05C0022C patent/FR05C0022I2/fr active Active
- 2005-05-09 NL NL300195C patent/NL300195I2/nl unknown
- 2005-05-24 NO NO2005014C patent/NO2005014I2/no unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0245486A (ja) * | 1988-06-27 | 1990-02-15 | Wellcome Found Ltd:The | 治療用ヌクレオシド類 |
WO1992015309A1 (en) * | 1991-03-06 | 1992-09-17 | The Wellcome Foundation Limited | Antiviral nucleoside combination |
JPH06234641A (ja) * | 1991-05-16 | 1994-08-23 | Glaxo Group Ltd | 抗ウイルス組合せ |
WO1993023021A2 (en) * | 1992-05-13 | 1993-11-25 | The Wellcome Foundation Limited | Therapeutic combinations |
EP1513917A1 (en) * | 2002-06-14 | 2005-03-16 | Degussa AG | Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9744181B2 (en) | 2003-01-14 | 2017-08-29 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10511682A (ja) | ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせ | |
EP0938321B1 (en) | Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv | |
US6432966B2 (en) | Antiviral combinations | |
EP0910386B1 (en) | Combinations comprising vx478, zidovudine and 1592u89 for use in the treatment of hiv | |
AU7912398A (en) | Antiviral combinations containing the carbocyclic nucleoside 1592u89 | |
KR20010075202A (ko) | 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제 | |
WO2000018383A2 (en) | Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester | |
TWI230610B (en) | Dosage kits and pharmaceutical compositions for treating HIV infections | |
JP2001509786A (ja) | Hivの治療に使用するためのvx478、ジドブジン、および/または1592u89を含んでなる組合わせ | |
AU8017298A (en) | Antiviral combinations containing the carbocyclic nucleoside 1592u89 | |
MXPA98010386A (en) | Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
R150 | Certificate of patent or registration of utility model |
Ref document number: 2954357 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070716 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080716 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110716 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110716 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130716 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130716 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |